3 Stocks Worth Following Right Now: Cadrenal Therapeutics (CVKD), Cuprina (CUPR), Cardiol Therapeutics (CRDL)

Market behavior in clinical-stage equities is frequently influenced by expectations surrounding upcoming milestones, including enrollment completion, interim analyses, and final data readouts. These events can significantly reshape outlooks, particularly when they occur in pivotal or registration-enabling studies.

Cadrenal Therapeutics Inc (CVKD)

Cadrenal Therapeutics Inc (NASDAQ: CVKD) opened the trading on May 11, 2026, with a bit cautious approach as it glided -9.32% to $5.52. During the day, the stock rose to $6.32 and sank to $5.47. Taking a long-term approach, CVKD posted a 52-week range of $4.21-$16.25.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is 16.82%. This publicly-traded company’s shares outstanding now amount to $2.51 million, simultaneously with a float of $2.23 million. The organization now has a market capitalization of $15.84 million.

Cuprina Holdings (Cayman) Ltd (CUPR)

Cuprina Holdings (Cayman) Ltd (NASDAQ: CUPR) started the day on May 11, 2026, with a price decrease of -3.36% at $0.27. During the day, the stock rose to $0.28 and sank to $0.27. Taking a long-term approach, CUPR posted a 52-week range of $0.24-$9.50.

It was noted that the giant of the Healthcare sector posted annual sales growth of -74.96% over the last 5 years. Meanwhile, its Annual Earnings per share during the time were -74.96%.  This publicly-traded company’s shares outstanding now amount to $7.37 million, simultaneously with a float of $7.37 million. The organization now has a market capitalization of $1.99 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term growth narrative through the advancement of next-generation therapies designed to address broader cardiovascular markets. By expanding beyond its lead indication, the company is positioning itself to participate in larger commercial opportunities tied to chronic heart disease and inflammation-driven cardiac dysfunction.

Market Momentum

As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares versus an average volume of 686,413 shares. The company currently maintains a market capitalization of $149.093M and a beta of 0.43, reflecting relatively moderate volatility for a development-stage biotech company. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 suggests substantial upside potential tied to future pipeline execution.

Pipeline Development: CRD-38

Cardiol is advancing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy targets inflammation and fibrosis, two biological processes strongly associated with progressive cardiac remodeling and declining heart function.

Commercial Opportunity

Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs each year. Despite multiple available therapies, a significant unmet need remains for treatments capable of directly addressing inflammatory and fibrotic disease mechanisms that contribute to long-term progression.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as a meaningful secondary value driver for Cardiol. Continued progress across both lead and pipeline assets may strengthen the company’s broader strategic positioning within cardiovascular biotechnology.